Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells.

Audrey GrainJocelyn Ollier Thierry Guillaume Patrice ChevallierBaptiste Le CalvezMarion EveillardBéatrice Clémenceau

Published in: Biomedicines (2023)

relapses of ALL remain sensitive to cell lysis mediated by T-cell effectors. In case of ALL relapses after immunotherapy, a large immunophenotype will make new therapies possible for controlling such high risk ALL.

Keyphrases

liver failure
single cell
nk cells
cell therapy
respiratory failure
drug induced
intensive care unit
mesenchymal stem cells
type iii